Immatics starts late-stage cancer vaccine study

Germany's Immatics Biotechnologies says its vaccinated the first first patients in a Phase III study IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.